Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder.

Papakostas GI.

J Clin Psychiatry. 2009;70 Suppl 5:18-22. doi: 10.4088/JCP.8157su1c.04. Review.

2.

S-adenosyl-methionine in depression: a comprehensive review of the literature.

Papakostas GI, Alpert JE, Fava M.

Curr Psychiatry Rep. 2003 Dec;5(6):460-6. Review.

PMID:
14609501
4.

S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.

Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M.

Am J Psychiatry. 2010 Aug;167(8):942-8. doi: 10.1176/appi.ajp.2009.09081198.

PMID:
20595412
5.

Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence.

Mischoulon D, Fava M.

Am J Clin Nutr. 2002 Nov;76(5):1158S-61S. Review.

6.

Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.

Ruhé HG, Huyser J, Swinkels JA, Schene AH.

J Clin Psychiatry. 2006 Dec;67(12):1836-55. Review.

PMID:
17194261
7.

[Use of antidepressant drugs in schizophrenic patients with depression].

Micallef J, Fakra E, Blin O.

Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French.

PMID:
16910628
8.

S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine.

Alpert JE, Papakostas G, Mischoulon D, Worthington JJ 3rd, Petersen T, Mahal Y, Burns A, Bottiglieri T, Nierenberg AA, Fava M.

J Clin Psychopharmacol. 2004 Dec;24(6):661-4.

PMID:
15538131
9.

Moclobemide: therapeutic use and clinical studies.

Bonnet U.

CNS Drug Rev. 2003 Spring;9(1):97-140. Review.

10.

Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder.

Papakostas GI.

J Clin Psychiatry. 2009;70 Suppl 6:16-25. doi: 10.4088/JCP.8133su1c.03. Review.

11.
13.

Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis.

Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA; Multiple Meta-Analyses of New-Generation Antidepressants (MANGA) Study Group..

CNS Drugs. 2008;22(7):587-602. Review.

PMID:
18547127
14.

Treating each and every depressed patient.

Kennedy SH.

J Psychopharmacol. 2008 Sep;22(7 Suppl):19-23. doi: 10.1177/0269881108093270. Review.

PMID:
18753279
16.

[Interest of the use of pindolol in the treatment of depression: review].

Brousse G, Schmitt A, Chereau I, Eschalier A, Dubray C, Llorca PM.

Encephale. 2003 Jul-Aug;29(4 Pt 1):338-50. Review. French.

PMID:
14615704
17.

Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine.

Fava M, Giannelli A, Rapisarda V, Patralia A, Guaraldi GP.

Psychiatry Res. 1995 Apr 28;56(3):295-7.

PMID:
7568552
18.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
19.

Folates and S-adenosylmethionine for major depressive disorder.

Papakostas GI, Cassiello CF, Iovieno N.

Can J Psychiatry. 2012 Jul;57(7):406-13. Review.

PMID:
22762295
Items per page

Supplemental Content

Support Center